News from polaris group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NYSE:PII)

Apr 29, 2014, 15:15 ET
Apr 02, 2014, 17:00 ET

Shaw T. Chen, M.D., Ph.D. joins Polaris

 Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) as...

Jan 27, 2014, 10:30 ET

Polaris Group's ADI-PEG 20 is a Radiosensitizer of Pancreatic Cancer

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, acts as a radiosensitizer of pancreatic...

Dec 02, 2013, 10:30 ET

Polaris Group Files New IND for ADI-PEG 20 in Leukemia

 Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...

Nov 06, 2013, 15:00 ET
Polaris Group.  (PRNewsFoto/Polaris Group)

Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia

 Polaris Group announced today that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated...

Oct 28, 2013, 07:00 ET

Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with...

Oct 25, 2013, 17:55 ET
Polaris is a Canadian LTL carrier that provides scheduled, daily service between its Southern Ontario base and all points in the U.S. and Western Canada. The recipient of many awards for its dedication to service excellence, it is particularly proud of this recognition of its commitment to environmental leadership.  (PRNewsFoto/Polaris Transportation Group)

Polaris Transport Receives US EPA 2013 SmartWay Excellence Award

TORONTO, Oct. 25, 2013 /PRNewswire/ - Polaris Transport was honored with a SmartWay® Excellence Award from the U.S. Environmental Protection...

Oct 22, 2013, 10:00 ET

Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer

 Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...

Apr 17, 2013, 10:00 ET
Jun 12, 2012, 09:00 ET
Feb 29, 2012, 10:29 ET

Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma

 Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer...

Jan 10, 2012, 09:00 ET

Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Combination with Docetaxel in Advanced Solid Tumors with Emphasis on Prostate Cancer

SAN DIEGO, Jan. 10, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1...

Jul 28, 2011, 08:00 ET

Polaris Group Doses First Patient in Pivotal Phase 3 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 for the Treatment of Hepatocellular Carcinoma

Polaris Group (Polaris) today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer...

May 18, 2011, 08:00 ET

Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris' Novel Cancer Drug, ADI-PEG 20

Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development...

May 12, 2011, 08:00 ET

Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan

Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine...

Apr 11, 2011, 10:13 ET

Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy

Polaris Group (Polaris) announced today that data from preclinical studies of ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic,...

Apr 08, 2011, 08:00 ET

Transcriptional Silencing of ASS1 Suggests the Potential Use of ADI-PEG 20 to Treat AML, Glioblastoma and Bladder Cancer

Polaris Group (Polaris) announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase...

Mar 31, 2011, 08:00 ET

FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group's Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma

Polaris Group (Polaris) today announced that the U.S. Food & Drug Administration (FDA) has approved the company's Special Protocol Assessment...

Mar 18, 2011, 09:52 ET

Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma

Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the...

Mar 15, 2011, 17:21 ET

Polaris Group Appoints Robert E. Hoffman as Chief Financial Officer

Polaris Group today announced the appointment of Robert E. Hoffman as chief financial officer. Hoffman has joined Polaris from Arena...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge